Leukemia Clinical Trials in Detroit

Showing 1361-1380 of 1,678 trials

Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia

NCT01363297

The Phase 1 portion of this study will assess the safety, tolerability and efficacy at increasing dose levels of inotuzumab ozogamicin in subjects with CD22-positive relapsed or refractory adult acute lymphocytic leukemia (ALL) in order to select the recommended phase 2 dose (RP2D) and schedule. The Phase 2 portion of the study will evaluate the efficacy of inotuzumab ozogamicin as measured by hematologic remission rate (CR + CRi) in patients in second or later salvage status.

Acute Lymphocytic Leukemia

Pfizer72 participantsStarted Aug 2011

Duarte, California, United States • Palo Alto, California, United States • Palo Alto, California, United States +12 more locations

COMPLETEDNA< 1 mile

Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia That Has Relapsed in the CNS or Testes

NCT00096135

RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Giving combination chemotherapy together with radiation therapy may kill more cancer cells. PURPOSE: This clinical trial is studying how well giving chemotherapy together with radiation therapy works in treating patients with acute lymphoblastic leukemia that has relapsed in the CNS and/or testes.

Leukemia

Children's Oncology Group168 participantsStarted Nov 2004

Birmingham, Alabama, United States • Phoenix, Arizona, United States • Tucson, Arizona, United States +150 more locations

Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia

Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia That Has Relapsed in the CNS or Testes

Leukemia Trials in Other Cities

Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy

Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer

Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia

Perennial Allergic Rhinitis Study In Pediatric Subjects

Guided Imagery in the Perioperative Period in Gynecologic Oncology Patients

Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC

Pharmacokinetics and Pharmacodynamics of Dexmedetomidine in Pediatrics Subjects

A Study Of Oral GW572016 In Advanced Or Metastatic Non-Small Cell Lung Cancer

Study in Pediatrics With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma

Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer

Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer

Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

Study of the Glutaminase Inhibitor CB-839 in Leukemia

Biomarker-based Cockroach Sublingual Immunotherapy Study (BioCSI)

Dose Range Study of Anamorelin in Patients With Non-small Cell Lung Cancer

Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors

Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous Therapy

A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations

Other Conditions in Detroit